Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bjh.14034 http://scihub22266oqcxt.onion/10.1111/bjh.14034 27030315!4917459!27030315     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27030315&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Br+J+Haematol 2016 ; 174 (1): 102-16 Nephropedia Template TP {{tp|p=27030315|t=2016. Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation |pdf=|usr=}}{{27030315}} gab.com Text Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation JO: Br J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=27030315 #FOAvip Advances in haploidentical bone marrow transplantation (h-BMT) have drastically broadened the treatment options for patients requiring BMT. The possibility of significantly reducing the complications resulting from graft-versus-host disease (GvHD) with the administration of post-transplant cyclophosphamide (PT-CY) has substantially improved the efficacy and applicability of T cell-replete h-BMT. However, higher frequency of disease recurrence remains a major challenge in h-BMT with PT-CY. There is a critical need to identify novel strategies to prevent GvHD while sparing the graft-versus-leukaemia (GvL) effect in h-BMT. To this end, we evaluated the impact of bendamustine (BEN), given post-transplant, on GvHD and GvL using clinically relevant murine h-BMT models. We provide results indicating that post-transplant bendamustine (PT-BEN) alleviates GvHD, significantly improving survival, while preserving engraftment and GvL effects. We further document that PT-BEN can mitigate GvHD even in the absence of Treg. Our results also indicate that PT-BEN is less myelosuppressive than PT-CY, significantly increasing the number and proportion of CD11b(+) Gr-1(hi) cells, while decreasing lymphoid cells. In vitro we observed that BEN enhances the suppressive function of myeloid-derived suppressor cells (MDSCs) while impairing the proliferation of T- and B-cells. These results advocate for the consideration of PT-BEN as a new therapeutic platform for clinical implementation in h-BMT. Twit Text FOAVip Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation ????Br J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=27030315 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27030315 #FOAvip English Wikipedia <ref>{{Cite pmid|27030315}}</ref> Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation #MMPMID27030315 Stokes J; Hoffman EA; Zeng Y; Larmonier N; Katsanis E Br J Haematol 2016[Jul]; 174 (1): 102-16 PMID27030315show ga Advances in haploidentical bone marrow transplantation (h-BMT) have drastically broadened the treatment options for patients requiring BMT. The possibility of significantly reducing the complications resulting from graft-versus-host disease (GvHD) with the administration of post-transplant cyclophosphamide (PT-CY) has substantially improved the efficacy and applicability of T cell-replete h-BMT. However, higher frequency of disease recurrence remains a major challenge in h-BMT with PT-CY. There is a critical need to identify novel strategies to prevent GvHD while sparing the graft-versus-leukaemia (GvL) effect in h-BMT. To this end, we evaluated the impact of bendamustine (BEN), given post-transplant, on GvHD and GvL using clinically relevant murine h-BMT models. We provide results indicating that post-transplant bendamustine (PT-BEN) alleviates GvHD, significantly improving survival, while preserving engraftment and GvL effects. We further document that PT-BEN can mitigate GvHD even in the absence of Treg. Our results also indicate that PT-BEN is less myelosuppressive than PT-CY, significantly increasing the number and proportion of CD11b(+) Gr-1(hi) cells, while decreasing lymphoid cells. In vitro we observed that BEN enhances the suppressive function of myeloid-derived suppressor cells (MDSCs) while impairing the proliferation of T- and B-cells. These results advocate for the consideration of PT-BEN as a new therapeutic platform for clinical implementation in h-BMT. |Animals[MESH] |Bendamustine Hydrochloride/*administration & dosage/pharmacology[MESH] |Bone Marrow Transplantation/*methods[MESH] |Cyclophosphamide/pharmacology[MESH] |Graft vs Host Disease/drug therapy/*prevention & control[MESH] |Graft vs Leukemia Effect/*drug effects[MESH] |Histocompatibility/immunology[MESH] |Immunosuppression Therapy[MESH] |Mice[MESH]Post-transplant bendamustine reduces GvHD while preserving GvL in expe(epmc).pdf DeepDyve Pubget Overpricing